Answer
No pharmacokinetic drug interactions are expected based on donanemab’s characteristics, although no interaction studies have been performed.
Sources for this answer
- Kisunla 350 mg concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked